Results 151 to 160 of about 260,886 (316)

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

From Basics to Benchmarks: Evaluating Sample Adequacy, PD‐L1 Expression, and Molecular Profiling in Effusion Samples of Lung Adenocarcinoma

Diagnostic Cytopathology, EarlyView.
ABSTRACT Introduction Lung adenocarcinoma commonly causes malignant pleural effusion (MPE), a condition with poor prognosis and limited treatment options. Pleural effusion specimens offer a minimally invasive source for diagnosis and molecular testing.
Harpreet Virk, Claire Michael, Keri Ann Pfeil, Navid Sadri, Omid Savari, Aparna Harbhajanka   +5 more
wiley   +1 more source

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

Cancer Management and Research, 2019
Ruxu You,1,* Jinyu Liu,2,* David Bin-Chia Wu,3 XinYu Qian,4 Boxiang Lyu,5 Yu Zhang,1 Nan Luo4 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China ...
You R, Liu J, Wu DBC, Qian X, Lyu B, Zhang Y, Luo N   +6 more
doaj  

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

, 2017
Michael Thomas,1,2 David R Spigel,3 Robert M Jotte,4 Michael McCleod,5 Mark A Socinski,6 Ray D Page,7 Laurent Gressot,8 Jeanna Knoble,9 Oscar Juan,10 Daniel Morgensztern,11 Dolores Isla,12 Edward S Kim,13 Howard West,14 Amy Ko,15 Teng Jin Ong,15 ...
Socinski MA, Juan O, Ong TJ, Morgensztern D, Ko A, Spigel DR, Kim ES, Trunova N, West H, Gridelli C, McCleod M, Page RD, Thomas M, Jotte RM, Gressot L, Isla D, Knoble J   +16 more
core  

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Next‐Generation Surgery: Integrating Artificial Intelligence, Genetic Technologies, Bioengineering and Rehabilitation Into Modern Practices

Exploration, EarlyView.
This graphic abstract depicts the convergence of artificial intelligence, genetic technologies, bioengineering, and rehabilitation as the core pillars of next‐generation surgery. These domains collectively enhance preoperative planning, intraoperative precision, tissue reconstruction, and postoperative recovery, driving a paradigm shift toward ...
Dengxiong Li, Jie Wang, Zhipeng Wang, Ruicheng Wu, Zhouting Tuo, Fanglin Shao, Wenjing Ge, Ziyu Shu, Yubo Yang, Dilinaer Wusiman, Qingxin Yu, Luxia Ye, Alisha Pati‐Alam, Facai Zhang, Koo Han Yoo, Susan Heavey, William C. Cho, Dechao Feng   +17 more
wiley   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

International Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn   +19 more
wiley   +1 more source

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France. [PDF]

Cancer Med
Debieuvre D, Macouillard P, Quantin X, Berktas M, Girard N, Audigier-Valette C, Filleron T, Musilli S, Bosquet L, Pérol M.   +9 more
europepmc   +1 more source

Risk–Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, EarlyView.
The therapeutic status of drug administration in phase 2 cancer trials is ambiguous, as these studies test efficacy without strong evidence of clinical benefit. Nonetheless, patients face meaningful risks. This review compared efficacy and safety of monotherapy drugs in phase 2 and phase 3 trials across six cancer types.
Charlotte Ouimet, Monica Rosu, Jonathan Kimmelman   +2 more
wiley   +1 more source

An autoantibody signature targeting cuproptosis-related proteins for non-small cell lung cancer detection and prognosis. [PDF]

PeerJ
Liu A, Zhang L, Yu P, Nie T, Cao X, Li J, Sun W, Liang Y, Ouyang S, Dai L, Liu J.   +10 more
europepmc   +1 more source